MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study [Yahoo! Finance]
MeiraGTx Holdings plc - Ordinary Shares (MGTX)
Company Research
Source: Yahoo! Finance
MeiraGTx Holdings ' MGTX clinical bridging study of its gene therapy candidate, AAV-GAD, for treating Parkinson's disease (PD) met its primary study objective of safety and tolerability. The stock soared 14.9% in response to the news. MGTX's PD Gene Therapy Candidate Betters Sham Treatment The MGT-GAD-025 study of AAV-GAD for PD demonstrated significant and clinically meaningful improvements from baseline for key efficacy endpoints after 26 weeks of treatment. Per the data readout, treatment with the candidate resulted in a statistically significant 18-point average improvement from baseline in the UPDRS Part 3 (motor examination) “off” medication score in the high-dose group at week 26. However, no significant change in the sham or low-dose groups was observed. Additionally, MeiraGTx reported significant dose-dependent improvements from baseline in the disease-specific, patient-reported quality of life PDQ-39 score in both the high and low-dose groups with no significant cha
Show less
Read more
Impact Snapshot
Event Time:
MGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGTX alerts
High impacting MeiraGTx Holdings plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MGTX
News
- MeiraGTx's Parkinson's gene therapy shows promise in Phase I/II study [Yahoo! Finance]Yahoo! Finance
- MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings [Seeking Alpha]Seeking Alpha
- MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s DiseaseGlobeNewswire
- Cell and Gene Therapy in Parkinson's Disease Clinical Trial Pipeline Analysis Demonstrates 18+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight [Yahoo! Finance]Yahoo! Finance
- MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience ConferenceGlobeNewswire
MGTX
Earnings
- 8/12/24 - Miss
MGTX
Sec Filings
- 10/15/24 - Form 8-K
- 8/14/24 - Form SC
- 8/14/24 - Form 4
- MGTX's page on the SEC website